MRIGlobal advances the detection and diagnosis of antimicrobial resistance, improving patient treatment outcomes.
Over time, bacteria and fungi evolve into stronger versions of themselves in order to defeat antibiotics. Each year, at least 35,000 people die as a result of antibiotic-resistant bacteria. MRIGlobal partners with both public and private clients to develop new tests and technologies to help fight antimicrobial resistance everywhere.
Discovery of new antimicrobial resistant biomarkers to improve detection and diagnostic technologies
Development and use of Next Generation Sequencing and bioinformatics methods to improve lab-based assays for the detection and diagnosis of antimicrobial resistant bacteria
Research to understand the prevalence of zoonotic bacteria that could confer high levels of antimicrobial resistance in both humans and animals
Testing of commercial technologies against diverse collections of microorganisms to evaluate their ability to detect antimicrobial disease markers in infectious disease agents
MRIGlobal scientists work in a Biological Safety Level laboratory, preparing samples for antimicrobial resistance testing.
MRIGlobal scientists develop, test, and evaluate methods for use with cutting-edge technologies to detect antimicrobial resistance markers in humans, animals, and the environment. Our work develops methods and technologies for antimicrobial resistance detection and surveillance, ultimately improving antibiotic stewardship and reducing the prevalence of antimicrobial resistance.
Work With Us